

Knowing your patient's cancer risks shapes personalized screening plans.



Clinical Breast Exam



PAP Test



Cancer Family History

Screen

(rate of abnormal)

7%¹

Evaluate

Palpable Mass/Screening Imaging Studies

Diagnose

Diagnostic Imaging Studies/Breast Biopsy

Result Rate

(% if abnormal screens)

Cancer Diagnosis:
Positive* **~10%**
Negative **~90%**

Manage

Develop a plan for appropriate medical management

5-10%²

ASCUS/HPV+, ASC-H, Low-Grade Squamous Lesions (LSIL), High-Grade Squamous Lesion (HSIL)

Colposcopy/Biopsy

Cancer Diagnosis:
Positive** **~2%**
Negative **~98%**

Develop a plan for appropriate medical management

20%^{3,4}

Significance of Cancer Family History

Hereditary Cancer Testing

Diagnosis of Hereditary Cancer Risk:
Positive (Mutation Identified)*** **up to 7%**
Negative for Mutation **~93%**

Develop a plan for appropriate medical management

References

1. Bobo JK, et al. *Journal of the National Cancer Institute*, Vol. 92, No. 12, June 21, 2000

2. <http://cancer.gov/cancertopics/factsheet/Detection/Pap-test>

3. Hughes K, et al. *The Breast Journal*: 2003 9(1):19-25 – Rate of Abnormal is defined by cancer family history meeting red flags.

*Lecia M Apantaku, MD I- Finch University of Health Sciences/The Chicago Medical School, North Chicago II – The American Academy of Family Physicians August 1, 2000 – Breast Cancer Diagnosis and Screening. **Wright TC Jr, Massad L.S, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *Am J Obstet Gynecol* 2007; 197:346. ***Kurian, A. et al. (2017). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *JCO Precision Oncology*, 1, 1-17. <https://doi.org/10.1200/PO.16.00066>



WORKFLOW SOLUTIONS SUPPORTING PATIENTS AND PROVIDERS AT EVERY STEP



DIGITAL HISTORY COLLECTION AND ASSESSMENT

Suite of digital tools collect & analyze patient medical & family history, assessing risk based on:

- hereditary cancer testing guidelines
- Tyrer-Cuzick breast cancer risk score

PRE-TEST EDUCATION

How genetic can guide personalized, proactive healthcare

GENETIC TESTING

Ordered through Ambry for qualified individuals

RESULTS DELIVERY

Results delivered to the provider, and in most cases, to the patient, using the CARE platform

POST-TEST GENETIC COUNSELING

Made available to all patients

DOCUMENTATION

Transparency at each step, improving patient and provider experience

Empower your patients to take proactive steps to manage their cancer risk.



SCAN HERE TO
LEARN MORE